# Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/AQST/aquestive-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update
Ticker: AQST
Company: Aquestive Therapeutics
Source: Aquestive Therapeutics
Published: 2026-03-04 21:01 EST
Original Source URL: https://investors.aquestive.com
## Summary

Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 days On track to submit regulatory applications for Anaphylm in Canada and the EU in 2026 Extends revenue sharing agreement with RTW to June 30, 2027

## Article Body
Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 days On track to submit regulatory applications for Anaphylm in Canada and the EU in 2026 Extends revenue sharing agreement with RTW to June 30, 2027
## Recent Company News
- 2026-05-13 20:01 EST — [Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Aquestive Therapeutics
- 2026-05-12 13:32 EST — [Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-completes-150-million-debt-refinancing-with-oaktree) — Source: Aquestive Therapeutics
- 2026-05-06 11:00 EST — [Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-business-highlights-on-may-13-and-host-conference-call-on-may-14-at-8-00-a-m-et) — Source: Aquestive Therapeutics
- 2026-03-30 11:00 EST — [Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-announces-completion-of-type-a-meeting-with-fda-for-anaphylmtm-dibutepinephrine-sublingual-film) — Source: Aquestive Therapeutics
- 2026-03-20 11:00 EST — [Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-announces-new-role-of-lori-j-braender-and-appointment-of-thomas-a-zalewski-as-chief-legal-officer-and-chief-compliance-officer) — Source: Aquestive Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)